Peregrine Receives FDA Approval to Proceed With Tarvacin(TM) Phase I Study

Peregrine Gains Access to Merck KGaA's Protein Expression Technology

Peregrine and New Approaches to Brain Tumor Therapy (NABTT) Consortium Receive Approval for Cotara(R) Brain Cancer Protocol

Peregrine Announces Second Quarter Financial Results

Peregrine Pharmaceuticals and New Approaches to Brain Tumor Therapy (NABTT) Consortium Enter Collaboration to Treat Brain Cancer Patients

Peregrine Pharmaceuticals and Affitech AS Expand Collaboration to Develop Up to Six New Fully Human Antibodies

Tarvacin(TM) Equivalent Plus Radiation Therapy Reduces Tumor Growth by 98%

Peregrine Pharmaceuticals Provides Tarvacin(TM) IND Update

Review of Peregrine's Phase I Cotara(R) Clinical Data for Colorectal Cancer to Be Presented at Cancer Therapy Meeting

Peregrine Announces the Appointment of Prominent Scientist to Its Scientific Advisory Board